Business Context and Reporting Period
BGM Group Ltd. (formerly Qilian International Holding Group Limited) is a Cayman Islands holding company with no material operations of its own. It conducts business primarily through Variable Interest Entities (VIEs) in the People's Republic of China (PRC), specifically Gansu Qilianshan Pharmaceutical Co., Ltd. (Gansu QLS) and its subsidiaries. The company operates in three main segments: Diversified Pharmaceutical and Allied Products (including oxytetracycline, licorice, and heparin), AI Solutions, and Insurance Business. This Form 20-F covers the fiscal year ended September 30, 2025.
Key Financial Metrics (Fiscal Year Ended Sept 30, 2025)
| Metric | 2025 (USD) | 2024 (USD) |
|---|---|---|
| Net Revenue | $37,919,425 | $25,097,951 |
| Gross Profit | $6,311,459 | $4,114,755 |
| Gross Margin | 16.6% | 16.4% |
| Net Loss | $(20,216,014) | $(1,517,161) |
| Net Loss Attributable to Shareholders | $(19,941,242) | $(1,442,830) |
| Cash and Cash Equivalents | $9,820,440 | $9,817,254 |
| Total Assets | $433,814,485 | $53,003,728 |
| Total Liabilities | $41,916,992 | $8,910,379 |
| Goodwill | $350,849,431 | $0 |
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased by 51% ($12.8 million) driven by the acquisition of AI Solutions and Insurance Business segments, which contributed $3.4 million and $11.0 million respectively. The legacy pharmaceutical segment revenue declined by 6% to $23.6 million.
- Significant Losses: Net loss attributable to shareholders surged by 1,282% to $19.9 million. This was primarily driven by a $7.7 million unrealized loss on trading securities (fair value change) and a $14.2 million increase in Selling, General, and Administrative (SG&A) expenses, largely due to stock-based compensation ($10.2 million) and expenses from acquired entities.
- Balance Sheet Expansion: Total assets increased nearly 8x to $433.8 million, almost entirely due to the recognition of $350.8 million in goodwill from four major acquisitions completed in late 2024 and 2025 (AI/Insurance, YX Management, Yang Lou Dong, and HM Management).
- Segment Margins: While the pharmaceutical segment margin compressed to 11% (from 16%), the new AI Solutions and Insurance segments reported margins of 44% and 19% respectively.
Guidance, Outlook, Risks, and Unusual Items
- Capital Needs: Management estimates a need for at least $50 million in capital over the next three years to fund expansion and acquisitions. The company plans to raise funds through equity or debt financing.
- Nasdaq Compliance: The company received a deficiency letter from Nasdaq on April 24, 2026, regarding the Minimum Bid Price Requirement (stock price below $1.00 for 30 consecutive days). It has 180 days to regain compliance, potentially via a reverse stock split.
- Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting due to a deficiency in the ability of in-house accounting professionals to generate US GAAP-compliant financial statements.
- VIE Structure Risk: The company relies on contractual arrangements to control its PRC operating entities. If PRC authorities deem these arrangements non-compliant, the company could be forced to deconsolidate the VIEs, potentially rendering shares worthless.
- Regulatory Risks: Significant risks exist regarding PRC government oversight, including potential delisting under the Holding Foreign Companies Accountable Act (HFCA) if auditors cannot be inspected, and uncertainties regarding data security and cybersecurity reviews.
- Unusual Items: The $7.7 million investment loss in trading securities is a non-cash fair value adjustment that significantly impacted the bottom line but did not affect operating cash flow.
Key Facts for Investor Verification
- Goodwill Valuation: Verify the valuation methodology for the $350.8 million in goodwill recorded from recent acquisitions, as this represents the majority of the company's asset base.
- Investment Loss: Confirm the nature and recoverability of the $7.7 million unrealized loss on trading securities and the underlying assets held.
- Stock-Based Compensation: Review the terms of the 2025 Equity Incentive Plan and the $10.2 million expense recognized, as this is a significant non-cash cost impacting profitability.
- Nasdaq Status: Monitor the company's progress in meeting the Nasdaq Minimum Bid Price requirement to avoid delisting.
- PRC Regulatory Filings: Verify the status of filings with the China Securities Regulatory Commission (CSRC) regarding recent share issuances and the company's compliance with overseas listing regulations.
- Internal Controls: Assess the remediation plan for the identified material weakness in internal financial reporting controls.